The ultimate goal of this project is the development of a novel therapeutic strategy for the treatment of cancer capitalizing on the unique antiproliferative effects of the alkaloid lycorine on apoptosis resistant cancers. Although a large majority of current cancer drugs exhibit their effects through the induction of apoptosis in tumor cells, many types of cancer, such as glioma, melanoma, NSCLC, among others, are resistant to proapoptotic stimuli and are typically associated with dismal prognoses. Therefore, new chemotypes that display antiproliferative effects against such apoptosis-resistant cancers and/or inhibit tumor metastatic spread are urgently needed. In preliminary work, the PI's collaborative chemical biology/drug discovery team has shown that the alkaloid lycorine modifies actin cytoskeleton organization in cancer cells, and impairs both their proliferation and migration. Lycorine exerts these effects with both apoptotic-resistant and susceptible cell lines, sensitizes cancer cells to proapoptotic agents, and displays 15 times greater potency toward cancer versus normal cells. Furthermore, lycorine showed significant therapeutic benefit in vivo in the B16F10 mouse melanoma model, consisting of orthotopically brain-grafted melanoma cells. These preliminary results form a compelling case for a thorough understanding of lycorine's mode of action in cancer cells and utilization of this knowledge for the development of novel strategies to treat cancers with dismal prognoses. The proposed work involves the preparation of lycorine- alkyne probes, which will be evaluated against a panel of apoptosis-resistant cancer cells with the goal of identifying derivatives retaining the antiproliferative potency and mode of action of lycorine. Suitable alkyne probes will then be used in protein pull-down assays, aimed at target protein identification. Several back-up target identification and target validation strategies are also proposed to confirm this innovative chemotherapeutic approach.

Public Health Relevance

This project is aimed at the ultimate goal of identifying new therapeutic strategies for the treatment of the types of cancer known to be associated with dismal prognosis, such as glioblastoma, melanoma, non-small-cell lung cancer, among others. It involves the elucidation of the intracellular target of the naturally occurring Amaryllidaceae alkaloid lycorine that has shown promising activity against such cancers in cell lines and in a mouse model of brain tumor.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Academic Research Enhancement Awards (AREA) (R15)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Arya, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Texas State University-San Marcos
Schools of Arts and Sciences
San Marcos
United States
Zip Code
Govindaraju, Karthik; Ingels, Aude; Hasan, Md Nabiul et al. (2018) Synthetic analogues of the montanine-type alkaloids with activity against apoptosis-resistant cancer cells. Bioorg Med Chem Lett 28:589-593
Govindaraju, Karthik; Masi, Marco; Colin, Margaux et al. (2018) Novel Topologically Complex Scaffold Derived from Alkaloid Haemanthamine. Molecules 23:
Dasari, Ramesh; La Clair, James J; Kornienko, Alexander (2017) Irreversible Protein Labeling by Paal-Knorr Conjugation. Chembiochem 18:1792-1796
Ciavatta, Maria Letizia; Lefranc, Florence; Carbone, Marianna et al. (2017) Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance. Med Res Rev 37:702-801
Carvalho, Annelise; Chu, Jennifer; Meinguet, Céline et al. (2017) A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis. Eur J Pharmacol 805:25-35
Carvalho, Annelise; Chu, Jennifer; Meinguet, Céline et al. (2017) Data in support of a harmine-derived beta-carboline in vitro effects in cancer cells through protein synthesis. Data Brief 12:546-551
Kornienko, Alexander; La Clair, James J (2017) Covalent modification of biological targets with natural products through Paal-Knorr pyrrole formation. Nat Prod Rep 34:1051-1060
Evdokimov, Nikolai M; Magedov, Igor V; McBrayer, Dominic et al. (2016) Isatin derivatives with activity against apoptosis-resistant cancer cells. Bioorg Med Chem Lett 26:1558-1560
Gomes, Nelson G M; Dasari, Ramesh; Chandra, Sunena et al. (2016) Marine Invertebrate Metabolites with Anticancer Activities: Solutions to the ""Supply Problem"". Mar Drugs 14:
Henry, Sean; Kidner, Ria; Reisenauer, Mary R et al. (2016) 5,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells. Eur J Med Chem 120:313-28

Showing the most recent 10 out of 22 publications